We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SPY icon
3026
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
-11,700
Closed -$5.02M
SSTI icon
3027
SoundThinking
SSTI
$106M
-6,745
Closed -$245K
STIM icon
3028
Neuronetics
STIM
$223M
-18,913
Closed -$124K
TAK icon
3029
Takeda Pharmaceutical
TAK
$55.6B
-5,518,932
Closed -$90.4M
TG icon
3030
Tredegar Corp
TG
$281M
-23,833
Closed -$290K
TLPH icon
3031
Talphera
TLPH
$72.7M
-3,020
Closed -$62K
VSTA
3032
DELISTED
Vasta Platform
VSTA
-49,057
Closed -$224K
WATT icon
3033
Energous
WATT
$93.4M
-234
Closed -$292K
XBIT icon
3034
XBiotech
XBIT
$75M
-12,154
Closed -$157K
XOMA
3035
DELISTED
Xoma
XOMA
-8,224
Closed -$204K
ATYR
3036
aTyr Pharma
ATYR
$53M
-12,024
Closed -$109K
INVX
3037
Innovex International
INVX
$2.13B
-832,517
Closed -$21M
TVRD
3038
Tvardi Therapeutics
TVRD
$22.1M
-28,842
Closed -$16M
SBT
3039
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
-1,338,260
Closed -$6.91M
EDR
3040
DELISTED
Endeavor Group Holdings, Inc.
EDR
-17,500
Closed -$502K
DNMR
3041
DELISTED
Danimer Scientific, Inc.
DNMR
-476
Closed -$311K
EGIO
3042
DELISTED
Edgio, Inc. Common Stock
EGIO
-265
Closed -$25K
DMTK
3043
DELISTED
DermTech, Inc. Common Stock
DMTK
-10,510
Closed -$337K
BCEL
3044
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
-18,134
Closed -$113K
ESMT
3045
DELISTED
EngageSmart, Inc.
ESMT
-22,615
Closed -$770K
ORTX
3046
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
-133,037
Closed -$3.06M
PRPC.U
3047
DELISTED
CC Neuberger Principal Holdings III Units, each consisting of one Class A ordinary share, and one-fifth of one redeemable warrant
PRPC.U
-60,625
Closed -$603K
TRHC
3048
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
-8,825
Closed -$231K
SCPL
3049
DELISTED
SciPlay Corporation Class A Common Stock
SCPL
-25,611
Closed -$530K
SDC
3050
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
-25,000
Closed -$133K

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.